Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms

British Journal of Cancer

Volumn 96, Issue 2, 2007, Pages 269-276

  Legrier, M E ^a   Oudard, S ^b   Judde, J G ^a   Guyader, C ^a   De Pinieux, G ^c   Boye K ^a   De Cremoux, P ^d   Dutrillaux, B ^a   Poupon, M F ^a  

^a INSERM U612   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Hôpital Cochin ^*  (France)

^d INSTITUT CURIE   (France)

Author keywords

Drug evaluation; Potentiation; Prostate adenocarcinoma; Protein expression

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P27; TRASTUZUMAB; TUBULIN; TYROSINE KINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SCREENING; MALE; MITOSIS SPINDLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33846468746     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603553     Document Type: Article

References (32)

1. Abal M, Andreu JM, Barasoain I (2003) Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3: 193-203
2. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW (1999) Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 59: 4761-4764
3. Burns RG, Islam K, Chapman R (1984) The multiple phosphorylation of the microtubule-associated protein MAP2 controls the MAP2:tubulin interaction. Eur J Biochem 141: 609-615
4. Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, Mohler JL (2003) Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 9: 1087-1097
5. Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-285
6. de Pinieux G, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Goncalves R, Dutrillaux AM, Nemati F, Oudard S, Lidereau R, Broqua P, Junien JL, Dutrillaux B, Poupon MF (2001) Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol 159: 753-764
7. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444
8. Edwards J, Krishna NS, Grigor KM, Bartlett JM (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89: 552-556
9. Fossa A, Lilleby W, Fossa SD, Gaudernack G, Torlakovic G, Berner A (2002) Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int J Cancer 99: 100-105
10. Georget V, Terouanne B, Nicolas JC, Sultan C (2002) Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41: 11824-11831
11. Haycock JW, Ahn NG, Cobb MH, Krebs EG (1992) ERK1 and ERK2, two microtubule-associated protein 2 kinases, mediate the phosphorylation of tyrosine hydroxylase at serine-31 in situ. Proc Natl Acad Sci USA 89: 2365-2369
12. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM (2004) Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 90: 449-454
13. Horne MM, Guadagno TM (2003) A requirement for MAP kinase in the assembly and maintenance of the mitotic spindle. J Cell Biol 161: 1021-1028
14. Horwitz SB (1994) Taxol (paclitaxel): mechanisms of action. Ann Oncol 5(Suppl 6): S3-S6
15. Lara Jr PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. (2004) Trastuzumab plus docetaxel in HER-2/neu-posotive prostate carcinoma: final results from the California Cancer Screening and Phase II Trial. Cancer 100(10): 2125-2131
16. Lara Jr PN, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, Tichauer G, Twardowski P, Doroshow JH, Gandara DR (2002) HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Trial. Cancer 94(10): 2584-2589
17. Legrier ME, de Pinieux G, Boye K, Arvelo F, Judde JG, Fontaine JJ, Bara J, Poupon MF (2004) Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft. Br J Cancer 90: 720-727
18. McDaid HM, Horwitz SB (2001) Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 60: 290-301
19. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL (2004) HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6: 517-527
20. Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D (2002) Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 62: 5485-5488
21. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C (2001) HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7: 2643-2647
22. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotte F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23: 3343-3351
23. Oudard S, Legrier ME, Boye K, Bras-Goncalves R, De Pinieux G, De Cremoux P, Poupon MF (2003) Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 169: 1729-1734
24. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Weitzman A, Judge T, England-Owen C, Zuech N, Pfaff C, Newhouse J, Bagiella E, Hetjan D, Sawczuk I, Benson M, Olsson C (1999) Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17: 958-967
25. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D (2001) HER2 protein expression and gene amplification in androgenin-dependent prostate cancer. Am J Clin Pathol 116: 234-239
26. Savinainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, Visakorpi T (2002) Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 160: 339-345
27. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ (2001) Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 166: 1514-1519
28. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schotzau A, Kononen J, Sauter G (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93: 1141-1146
29. Small EJ, Bok R, Reese DM, Sudilvsky D, Frohlich M (2001) Doetaxel, estramustine, plus trastuzumab in patients with metastatic androgenindependent prostate cancer. Semin Oncol 28(4 Suppl 15): 71-76
30. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034
31. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96: 5458-5463
32. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R, Lin MF (2003) ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 107: 478-485